Peripheral white blood cell therapeutics - Aposcience

Drug Profile

Peripheral white blood cell therapeutics - Aposcience

Alternative Names: APO-1; APO-2; APOSEC

Latest Information Update: 10 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aposcience
  • Developer Aposcience; Medical University of Vienna
  • Class Cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell replacements; Epithelial cell stimulants; Platelet aggregation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetic foot ulcer; Myocardial infarction; Wounds

Most Recent Events

  • 10 Mar 2016 Peripheral white blood cell therapeutics - Aposcience is available for licensing as of 10 Mar 2016.
  • 09 Mar 2016 Preclinical trials in Diabetic foot ulcer in Austria (Topical)
  • 09 Mar 2016 Preclinical trials in Myocardial infarction in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top